178 related articles for article (PubMed ID: 16051955)
1. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
Mian S; Ugurel S; Parkinson E; Schlenzka I; Dryden I; Lancashire L; Ball G; Creaser C; Rees R; Schadendorf D
J Clin Oncol; 2005 Aug; 23(22):5088-93. PubMed ID: 16051955
[TBL] [Abstract][Full Text] [Related]
2. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
3. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
4. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
5. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
6. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry.
Wilson LL; Tran L; Morton DL; Hoon DS
Ann N Y Acad Sci; 2004 Jun; 1022():317-22. PubMed ID: 15251977
[TBL] [Abstract][Full Text] [Related]
7. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
Greco M; Mitri MD; Chiriacò F; Leo G; Brienza E; Maffia M
Cancer Lett; 2009 Oct; 283(2):222-9. PubMed ID: 19394758
[TBL] [Abstract][Full Text] [Related]
8. [Serum diagnosis of head and neck squamous cell carcinoma using surface-enhanced desorption ionization mass spectrometry and artificial neural network analyses].
Cao SM; Guo X; Chen FJ; Yang AK; Chen WK; Li NW
Ai Zheng; 2007 Jul; 26(7):767-70. PubMed ID: 17626756
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
10. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
11. Predicting clinical outcome through molecular profiling in stage III melanoma.
John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
[TBL] [Abstract][Full Text] [Related]
12. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
[TBL] [Abstract][Full Text] [Related]
13. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
14. [Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
Lakomý R'; Greplová K; Pilný R; Budinská E; Valík D; Poprach A; Nemecek R; Vyzula R
Klin Onkol; 2009; 22(5):228-32. PubMed ID: 19886361
[TBL] [Abstract][Full Text] [Related]
15. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics.
Zhou L; Cheng L; Tao L; Jia X; Lu Y; Liao P
Acta Otolaryngol; 2006 Aug; 126(8):853-60. PubMed ID: 16846929
[TBL] [Abstract][Full Text] [Related]
16. [Surface enhanced laser desorption/ionization time-of-flight mass spectrometry profiling of serum in detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis].
Cheng L; Zhou L; Tao L; Zhang M; Cui JF; Liu YK
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2526-30. PubMed ID: 18067823
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
18. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
